Navigation Links
PharmAthene Reports First Quarter 2009 Financial and Operational Results
Date:5/15/2009

partially offset by reduced travel and other administrative overhead costs.

For the first quarter of 2009 PharmAthene's net loss attributable to common shareholders was $6.0 million or $0.23 per share, compared to $4.7 million or $0.22 per share in the same period of 2008.

PharmAthene's available cash, cash equivalents and short term investments at March 31, 2009 totaled $24.0 million, which excludes restricted cash totaling $9.0 million. For the period ended December 31, 2008, the Company's available cash, cash equivalents and short term investments were $22.9 million, excluding restricted cash of $12.0 million. The increase in cash, cash equivalents and short-term investments at March 31, 2009 from December 31, 2008 is primarily attributable to the receipt of approximately $5.0 million in net proceeds from the public offering of common stock and warrants completed in March 2009, partially offset by funding of operations and the repayment of debt.

David P. Wright, President and Chief Executive Officer of PharmAthene, noted, "The first quarter of 2009 was a productive one for PharmAthene. In addition, we have recently met with senior officials at the Biomedical Advanced Research and Development Authority (BARDA) to discuss the pending FDA submission of our comprehensive regulatory strategy for SparVax(TM) under the recently amended RFP. We submitted a copy of the plan to BARDA last week for review. BARDA officials indicated a willingness to review our proposal when received and we remain on target to meet our stated goal of submitting our plan to FDA by May 21, 2009."

Mr. Wright continued, "BARDA has recently assumed responsibility for funding and oversight of activities under our previous contract for the development of SparVax(TM) with the National Institute of Allergy and Infectious Diseases (NIAID). The scope of work under the BARDA contract, which took effect April 1, 2009, will cover
'/>"/>

SOURCE PharmAthene, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
2. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
3. PharmAthene Named as Contractor in $13.9 Million Award Notice Published by the Department of Health and Human Services
4. Delaware Court Denies Motion by SIGA Technologies Seeking to Dismiss PharmAthenes Legal Action in Breach of Contract Lawsuit Against SIGA
5. PharmAthene to Present at the BIO CEO & Investor Conference 2008
6. PharmAthene Enhances Executive Leadership Team and Appoints Joan Fusco, Ph.D. Senior Vice President of Operations
7. PharmAthene Completes Pharmacokinetic Studies of Protexia(R); Program on Target for IND Filing in 2008
8. PharmAthene to Present at the Cowen and Company 28th Annual Health Care Conference
9. PharmAthene Signs Definitive Agreement to Acquire Biodefense Vaccines Business From Avecia
10. PharmAthene to Delay Release of Full Year 2007 Financial Results
11. PharmAthene Year-End 2007 Earnings Conference Call and Webcast Scheduled for Monday, March 31, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... Israel , July 23, 2014 ... a portfolio company of Trendlines Agtech , ... of Israel,s leading agricultural ... , Valentis,s technology combines nanocrystalline cellulose ... pulp waste, with additional nanoparticles to produce highly ...
(Date:7/23/2014)... 2014 Shire plc (LSE: ... specialty biopharmaceutical company, and ArmaGen, a US privately ... and collaboration agreement for AGT-182, an investigational enzyme ... both the central nervous system (CNS) and somatic ... This collaboration strengthens Shire,s rare disease pipeline of ...
(Date:7/23/2014)... California (PRWEB) July 23, 2014 With the ... in HD resolution for more than 15 minutes, Fastec Imaging ... the world of high speed imaging. “Finally, a high speed ... camera we use in our everyday lives.” proclaims Matt Kearney, ... Fastec has always been to demystify and simplify the traditionally ...
(Date:7/23/2014)... 2014 Astra Nova Training ... consultancy and pharma training services, and the ... , a non-profit integrating the expertise and investments ... a global system for clinical trials, are pleased ... the expertise of industry professionals through improved and ...
Breaking Biology Technology:Valentis Nanotech Signs MOU to Integrate Technology in Thermoplastics Production 2Shire Enters Strategic Licensing and Collaboration Agreement With ArmaGen 2Shire Enters Strategic Licensing and Collaboration Agreement With ArmaGen 3Shire Enters Strategic Licensing and Collaboration Agreement With ArmaGen 4Shire Enters Strategic Licensing and Collaboration Agreement With ArmaGen 5Fastec Imaging Introduces the First High Speed Camcorder 2Fastec Imaging Introduces the First High Speed Camcorder 3Astra Nova and ACRES Partner on Quality and Access of Training for Research Professionals 2Astra Nova and ACRES Partner on Quality and Access of Training for Research Professionals 3
... Mass., Sept. 17 Interleukin Genetics,(Amex: ILI ... Scientific,Officer, Kenneth Kornman, DDS, PhD, will present at ... Alexandria, VA. The conference will,focus on innovative methods ... Among a group of presenters that includes industry ...
... Bio IV NVS Strategic Fund L.P. invests $10 ... Radius Health ("Radius"),announced today that it has ... to,obtain an exclusive worldwide license (except Japan) to ... drug,candidate. BA058 is a proprietary analog of hPTHrP ...
... Medical School researchers have successfully synthesized a DNA-based memory ... step forward in the emerging field of synthetic biology. ... DNA, researchers in the lab of Professor Pamela Silver, ... Systems Biology, not only reconstructed the dynamics of memory, ...
Cached Biology Technology:Interleukin Genetics President and Chief Scientific Officer to Present at Immunotoxicology V Conference 2Interleukin Genetics President and Chief Scientific Officer to Present at Immunotoxicology V Conference 3Radius Grants Major Pharmaceutical Company Exclusive Option to License BA058 for Osteoporosis 2Scientists synthesize memory in yeast cells 2Scientists synthesize memory in yeast cells 3
(Date:7/23/2014)... Springer will publish the International Journal of Fuzzy ... the Taiwan Fuzzy Systems Association (TFSA). The cooperation will ... the area of fuzzy research., The International Journal ... papers that deal with the theory, design and application ... extension theory systems ranging from hardware to software. Launched ...
(Date:7/23/2014)... , July 23, 2014   MedNet Solutions ... in clinical study management systems, is pleased to ... proven life sciences industry executive with over 25 ... Officer (COO).  Clareece will be responsible for MedNet,s ... operational efficiency and quality product/service delivery.  ...
(Date:7/23/2014)... the principal bacteria that cause dental caries, has ... time, possibly coinciding with dietary change linked to ... in a study by researchers from the Universitat ... de Genmica para la Biodiversidad (National Laboratory of ... first time, have sequenced genetic material from this ...
Breaking Biology News(10 mins):MedNet Appoints Clareece West As Chief Operating Officer 2Ancient genetic material from caries bacterium obtained for the first time 2
... For the first time, researchers at the University of ... to tap into nitrogen found in rocks, boosting the trees, ... the atmosphere. Given that carbon dioxide is the most ... how rapidly the earth will warm in the future, the ...
... CREEK, Calif.Understanding the flow and processing of carbon in ... surface, is central to understanding global climate cycles, with ... below the ocean surface exists a "twilight zone" where ... this, it is known that microbes resident at these ...
... Examining brain damage that occurs when fetuses in the ... Institute have discovered that damage does not occur randomly but ... fatty molecule called LPA, acting through a receptor that transfers ... mice suggests that LPA may also be linked to the ...
Cached Biology News:Bedrock nitrogen may help forests buffer climate change, study finds 2Bedrock nitrogen may help forests buffer climate change, study finds 3Up from the depths: How bacteria capture carbon in the 'twilight zone' 2Discovery suggests way to block fetal brain damage produced by oxygen deprivation 2Discovery suggests way to block fetal brain damage produced by oxygen deprivation 3
Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
Normal serum collected from healthy Kunming mice....
Request Info...
Biology Products: